UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

INOGEN, INC.

(Exact name of Registrant as Specified in Its Charter)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Stanislav Glezer Separation Agreement

As previously announced in the Current Report on Form 8-K filed by Inogen, Inc. (the “Company”), dated April 11, 2024, the Company and Dr. Stanislav Glezer, Executive Vice President, R&D and Chief Medical Officer of the Company, mutually determined that Dr. Glezer would separate from the Company on or before May 3, 2024. Dr. Glezer’s role as an officer and employee of the Company ended effective April 11, 2024 (the “Separation Date”). In connection with the separation of Dr. Glezer’s employment with the Company, on May 13, 2024, Dr. Glezer and the Company entered into a separation agreement and release related to the termination of Dr. Glezer’s employment with the Company (the “Separation Agreement”).

The Separation Agreement provides that, subject to (a) Dr. Glezer’s execution of the Separation Agreement, (b) the Separation Agreement becoming effective, and (c) Dr. Glezer’s continued compliance with the terms of the Separation Agreement, the Company will provide Dr. Glezer with the severance benefits consistent with Dr. Glezer’s Amended and Restated Employment and Severance Agreement with the Company, dated October 11, 2021.

The summary of the Separation Agreement set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.